What is the connection between Hidradenitis Suppurativa (HS) and Ankylosing Spondylitis (AS)?

Both HS and AS are chronic inflammatory conditions with shared genetic predispositions and immune pathways, particularly involving the IL-17/IL-23 axis. Research suggests a causal relationship where AS can increase the risk of developing HS.

How common is it to have both HS and AS?

Studies indicate a higher prevalence of HS in patients with axial spondyloarthritis (which includes AS), with some reports showing HS prevalence as high as 9.1% in this group, compared to 1-4% in the general population. Conversely, a smaller percentage of HS patients develop AS.

Are there shared genetic factors between HS and AS?

Yes, both conditions are associated with the HLA-B27 gene, a key genetic marker for AS. The causal link between AS and HS is thought to be mediated by shared genetic architectures in IL-17/IL-23-related pathways.

What are the treatment implications for individuals with both HS and AS?

Treatment often involves a multidisciplinary approach. Biologic therapies, such as TNF-alpha inhibitors (e.g., adalimumab) and IL-17 inhibitors (e.g., secukinumab), are effective for both conditions. Coordinated care between dermatologists and rheumatologists is crucial to manage symptoms and optimize outcomes.

What are the warning signs of AS for someone with HS?

Warning signs include chronic back pain that improves with exercise but not rest, morning stiffness lasting more than 30 minutes, pain in the buttocks, heels, or other joints, and fatigue. If you have HS and experience these symptoms, consult your doctor for evaluation.

Comorbidity Deep-Dive

Hidradenitis Suppurativa and Ankylosing Spondylitis: Unraveling the Inflammatory Link

Hidradenitis Suppurativa (HS) and Ankylosing Spondylitis (AS) are chronic inflammatory conditions that often coexist. Understanding their shared genetic and immunological pathways is crucial for effective diagnosis and integrated management.

3.5x

Increased risk of AS in HS patients [1]

9.1%

Prevalence of HS in axial SpA patients [2]

80-90%

AS patients carry HLA-B27 gene [3]

IL-17/IL-23

Shared inflammatory pathway [4]

Why the Connection? Understanding the Overlap

Both Hidradenitis Suppurativa and Ankylosing Spondylitis are systemic inflammatory diseases, meaning they involve the body's immune system attacking its own tissues. This shared inflammatory nature, coupled with common genetic predispositions like the HLA-B27 gene and dysregulation of the IL-17/IL-23 immune pathways, creates a significant biological overlap. Recognizing this connection is vital for comprehensive care, as managing one condition can often influence the other.

The Science Behind the Link: Shared Mechanisms

Genetic Predisposition - HLA-B27

A significant genetic link between HS and AS is the Human Leukocyte Antigen B27 (HLA-B27) gene. While not everyone with HLA-B27 develops AS, a large majority of AS patients carry this gene [3]. Emerging research suggests that HLA-B27 misfolding in AS can trigger endoplasmic reticulum (ER) stress and overproduction of IL-23, which in turn primes immune cells to secrete IL-17A, a cytokine implicated in both AS and HS pathogenesis [4].

Dysregulated Immune Response - The IL-17/IL-23 Axis

Both HS and AS are characterized by an overactive immune response, particularly involving the IL-17/IL-23 cytokine axis. This pathway plays a critical role in chronic inflammation. In HS, elevated levels of IL-17-expressing T cells are found in lesional skin, while in AS, this pathway drives joint inflammation. The shared dysregulation of this axis provides a common therapeutic target for both conditions [4, 5].

Systemic Inflammation and Oxidative Stress

Beyond specific genetic markers, both HS and AS are driven by systemic inflammation. This chronic inflammatory state can lead to increased oxidative stress, which further contributes to tissue damage and disease progression in both conditions. The presence of one condition may exacerbate the inflammatory burden, potentially influencing the severity or onset of the other [6].

Treatment Overlap: Managing Both Conditions

Given their shared inflammatory mechanisms, some treatments are effective for both HS and AS, highlighting the importance of integrated care.

Treatment Category	HS Application	AS Application	Shared Benefit
Biologic Therapies (TNF-alpha inhibitors)	Reduces inflammation, lesion formation, and pain (e.g., Adalimumab) [7]	Decreases inflammation, pain, and stiffness in joints and spine (e.g., Adalimumab) [8]	Targets systemic inflammation, improving symptoms in both conditions.
Biologic Therapies (IL-17 inhibitors)	Reduces inflammation and improves skin lesions (e.g., Secukinumab) [9]	Significantly reduces disease activity and improves physical function (e.g., Secukinumab) [10]	Specifically targets the IL-17 pathway, a key driver in both diseases.
NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)	Manages pain and inflammation associated with flares.	First-line treatment for pain and stiffness in the spine and other joints.	Provides symptomatic relief from pain and inflammation.
Corticosteroids	Used for acute flare management to reduce severe inflammation.	Used for short-term management of severe inflammation or flares.	Potent anti-inflammatory effects for short-term symptom control.
Lifestyle Modifications	Dietary changes, smoking cessation, weight management.	Regular exercise, physical therapy, smoking cessation.	Supports overall health, reduces inflammation, and improves quality of life.

Warning Signs of Ankylosing Spondylitis in HS Patients

If you have HS, it's important to be aware of potential symptoms of AS, especially given the increased risk. Early diagnosis and intervention can significantly improve outcomes.

Key Symptoms to Monitor:

Chronic Back Pain: Pain in the lower back and buttocks that develops gradually, is worse in the morning or after periods of inactivity, and improves with exercise.
Morning Stiffness: Prolonged stiffness in the back, often lasting more than 30 minutes, that eases throughout the day with activity.
Pain in Other Joints: Inflammation and pain in other areas, such as the hips, shoulders, knees, or heels (enthesitis).
Fatigue: Persistent and overwhelming tiredness, a common symptom of chronic inflammatory conditions.
Reduced Flexibility: Progressive loss of spinal flexibility, making it difficult to bend or twist.
Eye Inflammation (Uveitis): Redness, pain, and light sensitivity in one or both eyes.

When to Seek Help - Coordinated Care:

If you experience any of these symptoms, especially if they are persistent or worsening, it is crucial to consult your healthcare provider. Given the overlap between HS and AS, a coordinated approach involving both your dermatologist and a rheumatologist is highly recommended.

Early referral to a rheumatologist can lead to timely diagnosis and initiation of appropriate treatment, which can prevent irreversible joint damage and improve your quality of life. Don't hesitate to discuss your concerns with your medical team.

Find a Specialist

Frequently Asked Questions

Take Control of Your HS Journey

Don't let Hidradenitis Suppurativa define you. Explore resources, connect with specialists, and find the support you need to manage your condition effectively.